PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 40

FDA Immunization 40

Pharmaceutical Technology

NOVEMBER 9, 2022

million, the think tank concluded in its updated evaluation. A previous October 2020 report concluded that longer-term safety and efficacy were needed to update health-benefit price benchmarks. million price tag. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. million ($1.8

FDA 111

FDA 111

pharmaphorum

NOVEMBER 19, 2021

million price tag make it is the most expensive treatment ever approved for NHS funding. Meanwhile, in Scotland, the drug is currently under evaluation by the Scottish Medicines Consortium (SMC) with a verdict expected in early 2022.

98

98

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. The post Risk-sharing agreements are growing at a rate of 24% appeared first on Pharmaceutical Technology. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

FDA 105

FDA 105

PharmaShots

MARCH 9, 2023

Other Affiliations: Angela is an active Board of Director member of the Pfizer Foundation (a charitable organization addressing global health challenges), European Federation of Pharmaceutical Industries and Associations (EFPIA), and UPS (the global leader in package delivery and supply chain logistics). LinkedIn Total experience: 35 yrs.

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

Pharmaceutical Technology

NOVEMBER 30, 2022

The Health Survey for England 2019 reported that 28% of adults in the UK were obese and 36.2% A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% Evaluate the effects of COVID-19 on the sector.

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

The Health Survey for England 2019 reported that 28% of adults in the UK were obese and 36.2% A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% Evaluate the effects of COVID-19 on the sector.

Insurance 98

Insurance Labelling Communication FDA 98

Pharmaceutical Technology

MARCH 17, 2023

GlobalData is the parent company of Pharmaceutical Technology. GlobalData calculates these risk scores by evaluating several qualitative and quantitative factors to establish the quality of conditions and the level of stability of the market access environment encountered by pharmaceutical companies in each country.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Communication 102